Lidocaine Injectable Syringes Recalled for Sterilization Assurance Concerns
CAPS Inc. is recalling 9,517 lidocaine 2% injectable syringes distributed nationwide due to lack of sterilization validation data. No illnesses have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall with a serious sterilization hazard in an injectable drug product. No illnesses or injuries have been reported, supporting a High severity level per the rubric.
Plain-English summary
Central Admixture Pharmacy Services Inc. (CAPS) is recalling 9,517 syringes of lidocaine 2% injection (20 mg/mL in 5 mL syringes) distributed nationwide. The product is a prescription-only injectable anesthetic.
The recall was initiated due to lack of assurance of sterility. The manufacturer has not provided validation data for sanitization cycles used in manufacturing, meaning there is no documented evidence that the sterilization processes effectively eliminate potential microorganisms from the final product.
Affected lot numbers include 17-271076 through 17-273771 with expiration dates from July 2023 through September 2023. Healthcare facilities and pharmacies that received these syringes should discontinue use immediately and return the product to CAPS Inc. or contact the FDA with questions.
No illnesses or injuries have been reported in connection with this recall. However, sterility failure in injectable products could result in serious infections if contaminated units were used in patient care.
The recalled product
- Product
- lidocaine 2%, 100 mg /5 mL, (20 mg/mL), 5 mL Syringe, Rx only, CAPS, Inc., 7935 Dunbrook Road, Suite C, San Diego, CA 92126, NDC: 71286-6006-1
- Manufacturer
- Central Admixture Pharmacy Services Inc
- Category
- Drug — Injectable anesthetic
- Affected units
- 9,517
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot: 17-271076
- Exp. 7/24/2023
- 17-271132
- 17-271165
- Exp. 7/25/2023
- 17-271230
- 17-271250
- Exp. 7/26/2023
- 17-271508
- Exp. 7/31/2023
- 17-271595
- 17-271604
- Exp. 8/1/2023
- 17-271658
- Exp. 8/2/2023
- 17-271764
- Exp. 8/3/2023
- 17-271826
- Exp. 8/6/2023
- 17-271972
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Central Admixture Pharmacy Services Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same manufacturer · Central Admixture Pharmacy Services Inc
See all →- ModeratePediatric TPN Bags Recalled for Incorrect Formulation
FDA (Drugs) · 2026-08-12
- SeverePediatric Total Parenteral Nutrition Bag Recalled for Incorrect Formulation
FDA (Drugs) · 2026-07-01
- SevereInjectable Phenylephrine Solution Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2025-03-19
- HighInjectable Lidocaine Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2023-10-11
- HighMidazolam Injectable Solution Recalled Over Sterility Assurance Concerns
FDA (Drugs) · 2023-10-11
Same hazard · sterility failure
See all →- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereTransvenous Pacing Electrode Tray with Bipolar Balloon Pacing Electrode Recalled
FDA (Devices) · 2026-07-22
- SevereArterial Line Kit with Lidocaine HCL Injection Fails Sterility Testing
FDA (Devices) · 2026-07-22
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22